Phase 3 'home run' in focal seizures, NDA filed, but MDD expansion worth multiples of epilepsy hinges on X-NOVA2 readout

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing azetukalner, an investigational targeted seizure drug not yet approved, for focal-onset seizures, with plans to expand into depression treatment.

Azetukalner posted the highest placebo-adjusted seizure reduction ever reported in a pivotal focal-onset-seizures trial, -42.7% on the 25 mg dose, and a pre-NDA meeting confirmed the FDA filing pathway. Approval in focal seizures is the near-term binary, but the thesis scales on whether X-NOVA2 validates the Kv7 channel as a depression target, an unproven mechanism in a crowded MDD field where most novel mechanisms have failed Phase 3. Praxis Precision Medicine's vormatrigine is the closest sodium-channel rival in epilepsy, though the more structurally important risk is a standard review rejection or a request for additional data given the NDA rests on two trials without a traditional placebo-controlled maintenance study.